TERAV

TeraV Therapeutics is a biotechnology company focused on developing next-generation CAR-T cell therapies for the treatment of solid tumors. Spun out of the University of Pennsylvania, the company leverages a proprietary platform targeting the Tn-glycoform of Mucin 1 (Tn-MUC1), a tumor-specific antigen widely expressed across various epithelial cancers. Their lead programs aim to overcome the challenges of the immunosuppressive tumor microenvironment to provide effective treatments for indications such as pancreatic and ovarian cancers. TeraV's approach combines advanced genetic engineering with deep expertise in glycobiology to create highly specific and potent cellular immunotherapies. The company's technology is designed to minimize off-tumor toxicity by specifically recognizing cancer-associated glyco-modifications. TeraV is currently advancing its lead candidates through IND-enabling studies to transition into clinical development.